Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Temozolomide Followed by Low-Dose Ipilimumab/Nivolumab Shows Potential in MSS and MGMT-Silenced mCRC

March 23rd 2022

Temozolomide priming followed by the combination of low-dose ipilimumab and nivolumab may produce durable clinical benefit in microsatellite stable and MGMT-silenced metastatic colorectal cancer.

Is There a Role for Single-Agent Immunotherapy in Advanced HCC?

March 23rd 2022

Experts in gastrointestinal cancers, Drs Pierre Gholam and Daneng Li, comment on the role of single-agent immunotherapy for first-line treatment of advanced HCC.

Frontline Therapies in Advanced HCC for Patients Unsuitable for Atezolizumab-Bevacizumab

March 23rd 2022

Pierre Gholam, MD, considers the optimal treatment selection for patients in whom an atezolizumab-bevacizumab combination isn’t a suitable frontline therapeutic option.

Which Patients With HCC Are Suitable for Treatment With Atezolizumab and Bevacizumab?

March 16th 2022

Nicole Rich, MD, reviews the patient selection for atezolizumab-bevacizumab and discusses patients in whom this regimen is contraindicated in the frontline setting in advanced HCC.

Phase 3 HIMALAYA Study in Advanced HCC

March 16th 2022

Dr Daneng Li reviews updated safety and efficacy results of durvalumab plus tremelimumab from the phase 3 HIMALAYA study in frontline unresectable HCC.

Frontline Cabozantinib/Atezolizumab Does Not Improve OS Over Sorafenib in Advanced HCC

March 15th 2022

The combination of cabozantinib and atezolizumab was not found to result in an improvement nor a detriment in overall survival vs sorafenib when used in previously untreated patients with advanced hepatocellular carcinoma, according to data from the phase 3 COSMIC-312 trial.

HER2 Expression Drives Treatment Decisions in Gastric/Esophageal Cancers

March 14th 2022

Experts in the field of upper gastrointestinal cancers discuss recent data from the European Society for Medical Oncology Congress 2021 that may bolster the uptake of HER2 as a guide for treatment decisions in the second line.

Investigators Look to Enhance Outcomes for Unresectable ESCC With Chemoradiation Combination

March 10th 2022

Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.

Phase 3 COSMIC-312 Study in Advanced HCC

March 9th 2022

Daneng Li, MD, evaluates the use of cabozantinib plus atezolizumab in first-line advanced unresectable HCC as seen in the COSMIC-312 study.

First-Line Systemic Treatment for Advanced HCC

March 9th 2022

Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.

Phase 3 NuTide:121 Study Examining NUC-1031 in Biliary Tract Cancer to be Discontinued

March 8th 2022

The phase 3 NuTide:121 trial examining the first-in-class nucleotide analogue NUC-1031 in combination with cisplatin vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer is being discontinued.

Cetuximab–Radionuclide Functionalized Polymeric Nanocomplexes: A Radiopharmaceutical Perspective for Liver Cancer

March 2nd 2022

Liver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors.

Nivolumab/Ipilimumab Nears EU Approval for Frontline PD-L1+ Unresectable Advanced, Recurrent or Metastatic ESCC

February 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab and ipilimumab for use in the frontline treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with a PD-L1 expression of 1% or higher.

EU Panel Recommends Frontline Nivolumab/Chemo for PD-L1+ Unresectable Advanced, Recurrent or Metastatic ESCC

February 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the use of nivolumab in combination with chemotherapy in the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with a PD-L1 expression of 1% or higher.

Nearly 300 Novel Agents Currently in Development for Rare Cancers

February 24th 2022

New agents for rare cancers make up approximately 35% of drugs in the pipeline for all rare diseases, according to a report from the Pharmaceutical Research and Manufacturers of America.

Sotorasib Shows Early Promise in Heavily Pretreated KRAS G12C–Mutated Advanced Pancreatic Cancer

February 23rd 2022

Sotorasib had clinically meaningful activity in heavily pretreated patients with KRAS G12C–mutated advanced pancreatic cancer, according to findings from the phase 1/2 CodeBreaK 100 trial.

Potential Applications of ctDNA Testing in Colorectal Cancer

February 15th 2022

An overview of the ctDNA testing platforms and the potential clinical applications of ctDNA testing across the colorectal cancer disease continuum.

MRD Testing in Solid Tumors

February 15th 2022

The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.

From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

February 11th 2022

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

Leading Investigator Seeks to Promote the Distinctions in GI Cancers

February 7th 2022

Michael A. Choti, MD, MBA, FACS, discusses the progress made in gastrointestinal cancers, plus the need to coordinate care between patients, oncologists, and surgeons.